Phase 3 Clinical Trials With Primary Completion Dates in February 2025
This is a list of Phase 3 trials with primary completion dates in February 2025 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.
The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.
| Symbol | Company | Primary Completion Date | Phase | NCT ID | Title |
|---|---|---|---|---|---|
| CANF | Can-Fite BioPharma Ltd. | 2025-02-01 | Phase 3 | NCT05201404 | Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis |
| CLRPF | Clarity Pharmaceuticals Ltd | 2025-02-01 | Phase 3 | NCT06056830 | Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy |
| CRSP | CRISPR Therapeutics AG | 2025-02-01 | Phase 3 | NCT05477563 | Evaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease |
| DNPUF | Sumitomo Pharma Co., Ltd. | 2025-02-01 | Phase 3 | NCT04756037 | Study of the Safety and Contraceptive Efficacy of Relugolix Combination Therapy in Women With Uterine Fibroids or Endometriosis Who Are at Risk for Pregnancy |
| GKOS | Glaukos Corporation | 2025-02-01 | Phase 3 | NCT06066645 | Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone |
| PTGX | Protagonist Therapeutics, Inc. | 2025-02-01 | Phase 3 | NCT05210790 | A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera |
| RVPH | Reviva Pharmaceuticals Holdings, Inc. | 2025-02-01 | Phase 3 | NCT05184335 | Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia |
| VPHIF | Valeo Pharma Inc. | 2025-02-01 | Phase 3 | NCT06153394 | Prolonged Hypercoagulability Following Major Liver Resection for Malignancy |